Stephan Mielke

17.2k total citations · 1 hit paper
110 papers, 3.7k citations indexed

About

Stephan Mielke is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Stephan Mielke has authored 110 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Hematology, 50 papers in Oncology and 39 papers in Immunology. Recurrent topics in Stephan Mielke's work include Hematopoietic Stem Cell Transplantation (51 papers), CAR-T cell therapy research (25 papers) and Immune Cell Function and Interaction (19 papers). Stephan Mielke is often cited by papers focused on Hematopoietic Stem Cell Transplantation (51 papers), CAR-T cell therapy research (25 papers) and Immune Cell Function and Interaction (19 papers). Stephan Mielke collaborates with scholars based in Germany, United States and Sweden. Stephan Mielke's co-authors include Bipin N. Savani, Katayoun Rezvani, K. Mross, Alex Sparreboom, A. John Barrett, Agnes S. M. Yong, A. John Barrett, Roger Kurlander, Keyvan Keyvanfar and Aldemar Montero and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Stephan Mielke

106 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

2022 186 citations Jeremy S. Abramson, Scott R. Solomon et al. Blood profile →

Peers

Countries citing papers authored by Stephan Mielke

Since Specialization

Citations

This map shows the geographic impact of Stephan Mielke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Mielke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Mielke more than expected).

Fields of papers citing papers by Stephan Mielke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Mielke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Mielke. The network helps show where Stephan Mielke may publish in the future.

Co-authorship network of co-authors of Stephan Mielke

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Mielke. A scholar is included among the top collaborators of Stephan Mielke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Mielke. Stephan Mielke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rediscovering nitroxoline: a metal-chelating agent bridging infection and cancer 2025 ·Drug Discovery Today ·Praveen Papareddy, Stephan Mielke, (unknown), Daniel Bachmann, Ewgenij Proschak, Thomas A. Wichelhaus, Kerstin Sander, Heiko Herwald	0
2	611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors 2024 ·Annals of Oncology ·(unknown), Andréas Mackensen, (unknown), Winfried Alsdorf, (unknown), Daniel Heudobler, (unknown), Antonia Busse, Stephan Mielke, Sander Bins, Guy Ungerechts, Carsten Bokemeyer, Sebastian Klobuch, Nadine Kutsch, Fabian Müller, (unknown), Zhong Wei, (unknown), (unknown), Uğur Şahin	7
3	Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients with r/r AML 2024 ·Blood ·Marion Subklewe, Nicolas Boissel, Stephan Mielke, Pere Barba, (unknown), Éric Deconinck, (unknown), (unknown), (unknown), Marina Deschamps, Christophe Ferrand, (unknown), Richard C.A. Sainson, Jens Hasskarl	1
4	Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen 2024 ·Future Oncology ·Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanová, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco J. Hernandez‐Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, K. OGASAWARA, Manali Kamdar	1
5	Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. 2024 ·Journal of Clinical Oncology ·Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanová, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco J. Hernandez‐Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Victor A. Chow, (unknown), Silvia Colicino, K. OGASAWARA, Lara Stepan, Jeremy S. Abramson	6
6	Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT 2023 ·Bone Marrow Transplantation ·Gesine Bug, Myriam Labopin, Riitta Niittyvuopio, Matthias Stelljes, Hans Christian Reinhardt, Inken Hilgendorf, Nicolaus Kröger, (unknown), Wolfgang Bethge, Kerstin Schäfer‐Eckart, Mareike Verbeek, Stephan Mielke, Kristina Carlson, Ali Bazarbachi, Alexandros Spyridonidis, Bipin N. Savani, Arnon Nagler, Mohamad Mohty	5
7	Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT 2023 ·Bone Marrow Transplantation ·Arnon Nagler, Myriam Labopin, Stephan Mielke, Jakob Passweg, Didier Blaise, Tobias Gedde‐Dahl, Jan J. Cornelissen, Urpu Salmenniemi, Ibrahim Yakoub‐Agha, Péter Reményi, Gèrard Socié, Gwendolyn Van Gorkom, Hélène Labussière‐Wallet, Xiao‐Jun Huang, (unknown), Jenny Byrne, Charles Craddock, Laimonas Griškevičius, Fabio Ciceri, Mohamad Mohty	7
8	Anamnestic expansion of Omicron-reactive CD8+ T cells after booster SARS-CoV-2 mRNA vaccination across different immunocompromised states 2023 ·The Journal of Immunology ·Thomas Müller, Takuya Sekine, (unknown), Julia Niessl, (unknown), Yu Gao, Curtis Cai, Piotr Nowak, Ola Blennow, Lotta Hansson, Stephan Mielke, Peter Bergman, Hans‐Gustaf Ljunggren, Annika C. Karlsson, Sunil Kumar Saini, Soo Aleman, Marcus Buggert	1
9	T cell receptor excision circles are potential predictors of survival in adult allogeneic hematopoietic stem cell transplantation recipients with acute myeloid leukemia 2022 ·Frontiers in Immunology ·(unknown), (unknown), (unknown), Stephan Mielke, (unknown), Johan Törlén, Michael Uhlin	6
10	Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation 2021 ·Diagnostics ·Eva Wagner-Drouet, Daniel Teschner, Christine Wolschke, Kerstin Schäfer‐Eckart, (unknown), Stephan Mielke, Martin Schreder, Guido Kobbe, Inken Hilgendorf, Stefan Klein, Mareike Verbeek, Markus Ditschkowski, Martina Koch, Monika Lindemann, (unknown), Anne Rascle, (unknown), Ludwig Deml, Ralf Wagner, Daniel Wolff	1
11	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia 2020 ·Bone Marrow Transplantation ·Ali Bazarbachi, Myriam Labopin, Didier Blaise, Édouard Forcade, Gèrard Socié, Ana Berceanu, Emanuele Angelucci, Claude‐Eric Bulabois, Nicolaus Kröger, Alessandro Rambaldi, Patrice Céballos, Stephan Mielke, Jean El Cheikh, Ibrahim Yakoub‐Agha, Bipin N. Savani, Alexandros Spyridonidis, Arnon Nagler, Mohamad Mohty	6
12	Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation—a retrospective analysis on seven patients 2019 ·Annals of Hematology ·P. Lamby, Daniel Wolff, Stephan Mielke, Goetz Ulrich Grigoleit, Per Ljungman, Inken Hilgendorf, Ernst Holler, Barbara Holler, Daniela Weber, W. Herr, Daniel Schiltz, Stefan Klein, Solomon A. Graf, (unknown), Jüergen H. Dolderer, Lukas Prantl	4
13	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT 2019 ·Leukemia ·Noga Shem‐Tov, Christophe Peczynski, Myriam Labopin, Maija Itälä‐Remes, Didier Blaise, Hélène Labussière‐Wallet, Gèrard Socié, Nicolaus Kröger, Stephan Mielke, Boris V. Afanasyev, Patrice Chevallier, Johanna Tischer, Grzegorz Helbig, Pavel Jindra, Zinaida Perić, Sebastian Giebel, Mohamad Mohty, Arnon Nagler	37
14	Colonoscopy in Acute Diverticulitis 2015 ·Visceral Medicine ·Manfred Gross, Joachim Labenz, Gereon Börsch, Arno J. Dormann, Alexander J. Eckardt, Ralf Kießlich, Stephan Mielke	1
15	Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis 2014 ·Bone Marrow Transplantation ·Stephan Mielke, Mathias Lutz, (unknown), Markus Kapp, (unknown), Julia Ammer, Hermann Einsele, Goetz Ulrich Grigoleit, Ernst Holler, Daniel Wolff	13
16	Selectively T Cell-Depleted Allografts from HLA-Matched Sibling Donors Followed by Low-Dose Posttransplantation Immunosuppression to Improve Transplantation Outcome in Patients with Hematologic Malignancies 2011 ·Biology of Blood and Marrow Transplantation ·Stephan Mielke, (unknown), Aarthi Shenoy, Vicki Fellowes, (unknown), David F. Stroncek, Susan F. Leitman, Richard Childs, Minoo Battiwalla, (unknown), (unknown), Bipin N. Savani, (unknown), A. John Barrett	34
17	Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h 2003 ·Anti-Cancer Drugs ·Stephan Mielke, K. Mross, Thomas Alexander Gerds, Anja Schmidt, (unknown), Dietmar Berger, W. Lange, Dirk Behringer	31
18	Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. 1997 ·PubMed ·H. Meden, Stephan Mielke, (unknown), (unknown), (unknown)	13
19	In vivoeffects of estrogens on oerbB-2 oncoprotein levels in chorionic villous tissue and maternal serum 1997 ·Gynecological Endocrinology ·Stephan Mielke, H. Meden, (unknown), W. Wuttke, W. Kühn	2
20	Serum levels of the c-erbB-2 (HER2/neu) encoded oncoprotein fragment p105 in normal pregnancies. 1997 ·PubMed ·H. Meden, Stephan Mielke, A. Schauer, Walter Kühn	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact